Research vials are not pharmacy drugs

A large share of the peptide internet is not talking about Ozempic. It is talking about research chemicals: vials labeled 'not for human consumption,' sold from companies that are not pharmacies, in strengths that do not appear on any label. That market runs on a legal and scientific ambiguity that is useful to sellers and dangerous to buyers.

Three different objects

• Approved drugs — manufactured under GMP, prescribed, dispensed, recalled if needed.
• Compounded drugs — legal in defined US pathways (503A, 503B) for eligible bulk substances, still a pharmacy product with constraints.
• Research chemicals — not drugs. No sterility guarantee that a regulator stands behind. The 'not for human use' line is not a vibe; it is the seller declining the drug-regulatory bargain.

What Category 2 means

When the FDA places a substance such as BPC-157 in Category 2 of its compounding lists, it is saying there are safety or characterization problems that make compounding inappropriate under those pathways. People still buy it. The listing is a regulatory fact, not a rumor.

Identity is a clinical problem

Independent testing of gray-market peptides has, across several investigations in adjacent markets (SARMs, research steroids, 'research peptides'), found under-dosing, over-dosing, and wrong sequences. If you cannot name the manufacturer under GMP and the lot, you do not know what you are looking at. Mechanism trivia does not fix that.

A peptide without a manufacturer, a lot, and a label is a hypothesis in a bottle.